Immune thrombocytopenic purpura: new biological therapy of an old disease

Current Medicinal Chemistry
Melda Comert OzkanGuray Saydam

Abstract

Immune Thrombocytopenic Purpura (ITP) is the most common autoimmune disorder that is caused by antibody- mediated destruction of thrombocytes and impaired megakaryocyte platelet production. ITP remains a diagnosis of exclusion. Recent pathophysiologic mechanisms and therapeutical approaches of ITP have emerged. Although steroids and intravenous immunglobulins (IVIg) have still been the main therapeutic strategies, a group of patients develop resistance to those eventually and there have been some biological treatment options such as rituximab especially in the last decade. In this review article, we have summarized the therapeutic options for patients with ITP and mainly focused on the timing and potential effects of biological agents.

Citations

Jul 22, 2016·Clinical Medicine Insights. Blood Disorders·Shosaku Nomura

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

Related Papers

Clinical Laboratory
Ryan J Hansen, Joseph P Balthasar
Hematology/oncology Clinics of North America
Bethan Psaila, James B Bussel
© 2021 Meta ULC. All rights reserved